Literature DB >> 11552666

Demographics and epidemiology of allergic and nonallergic rhinitis.

R A Settipane1.   

Abstract

Chronic rhinitis symptoms are among the most common problems presenting to physicians. When approaching this problem the diagnostic challenge is to determine the etiology, whether it is allergic, nonallergic, or perhaps an overlap of both conditions. Estimates of the prevalence of allergic rhinitis range from as low as 9% to as high as 42%. Although nonallergic rhinitis is a well-recognized diagnosis, its prevalence has not been studied definitively. If the assumption is made that approximately 20% of the U.S. population has allergic rhinitis, then 58 million people in the United States suffer from this diagnosis. Population survey results have estimated that 19 million Americans suffer from nonallergic rhinitis. Frequently, nonallergic rhinitis occurs in tandem with allergic disease and presents as mixed rhinitis. Because 44% of patients with allergic rhinitis may have concomitant nonallergic rhinitis, it is estimated that an additional 26 million people have a nonallergic component to their rhinitis (mixed rhinitis). Therefore, a total estimated 45 million people have either pure nonallergic rhinitis or mixed rhinitis. Because nonallergic rhinitis is common, it is important to differentiate this condition from rhinitis of allergic etiology. Once the diagnosis is established, an appropriate treatment plan tailored to a specific diagnosis can be optimally designed.

Entities:  

Mesh:

Year:  2001        PMID: 11552666

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  23 in total

1.  Allergic and Non-Allergic Rhinitis Are Common in Obstructive Sleep Apnea but Not Associated With Disease Severity.

Authors:  Ming Zheng; Xiangdong Wang; Siqi Ge; Ying Gu; Xiu Ding; Yuhuan Zhang; Jingying Ye; Luo Zhang
Journal:  J Clin Sleep Med       Date:  2017-08-15       Impact factor: 4.062

2.  Bone marrow-derived mesenchymal stem cells reduce immune reaction in a mouse model of allergic rhinitis.

Authors:  Ning Zhao; Yanjuan Liu; Hongfeng Liang; Xuejun Jiang
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

Review 3.  Improving the management of atopic disease.

Authors:  S T Holgate; G Lack
Journal:  Arch Dis Child       Date:  2005-08       Impact factor: 3.791

Review 4.  Clinical practice. Allergic rhinitis.

Authors:  Lisa M Wheatley; Alkis Togias
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

5.  A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis.

Authors:  Jonathan A Bernstein; Benjamin P Davis; Jillian K Picard; Jennifer P Cooper; Shu Zheng; Linda S Levin
Journal:  Ann Allergy Asthma Immunol       Date:  2011-06-29       Impact factor: 6.347

6.  Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006.

Authors:  Päivi M Salo; Agustin Calatroni; Peter J Gergen; Jane A Hoppin; Michelle L Sever; Renee Jaramillo; Samuel J Arbes; Darryl C Zeldin
Journal:  J Allergy Clin Immunol       Date:  2011-02-12       Impact factor: 10.793

7.  Comparative Study of Apo-Cetirizine Single Therapy and Intermittent Sequential Therapy with Cetirizine, Loratadine and Chlorpheniramine in Allergic Rhinitis.

Authors:  Ali Safavi Naini; Jahangir Ghorbani; Ebrahim Mazloom
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-08-06

8.  Safety and tolerability of fluticasone furoate nasal spray once daily in paediatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicentre studies.

Authors:  Eli O Meltzer; Ita Tripathy; Jorge F Máspero; Wei Wu; Ed Philpot
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

9.  Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.

Authors:  Robert J Noveck; Richard A Preston; Suzanne K Swan
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis.

Authors:  Friedrich Horak
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.